The role of biomarkers in early diagnostics of inflammatory diseases of intestine in newborns
Heading: Pediatrics Article type: Review
Authors: Chernenkov Yu.V., Pozgaleva N.V. Panina OS.
Organization: Saratov State Medical University
Information on noninvasive biomarkers and methods for studying inflammatory bowel diseases in newborns has been summarized. It is based on the analysis of data taken from foreign and Russian literature. The need for additional study of factors affecting the level of fecal protein production in newborns is substantiated.
Bibliography:
1. Burtsev DV, Maksimov AYu, llyashenko MG, Tarasova GN. Multi-stage system of diagnostics of inflammatory and tumor diseases of the tolstous intelligence. Fundamental Research 2012; 7 (1): 54-57
2. Burri Е, Manz М, Rothen С, et al. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clin Chim Acta 2013 Feb; (41): 7
3. D'HaensG, Ferrante M, VermeireS,etal. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease 2012; 12 (22): 18-24
4. Canani BR. Diagnostic value of fecal calprotectin in paediatric gastroenterology clinical practice Dig Liver Dis 2004; (36): 467-470
5. Manz M, Burri E,Rothen C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. ВМС Gastroenterology 2012; (12): 5
6. Vedeniktova MM, Sharov AA, PotapovAS, et al. Confocal endomicroscopy in the diagnosis of inflammatory bowel diseases in children. Diagnostic issues in pediatrics 2012; 4 (3): 17-21
7. Van de Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. Journal of Digestive Diseases 2013; 14 (2): 62-67
8. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn disease. Gut 2005; (54): 364-368
9. Dai Z, Chen Z, Ye H, et al. Characterization of micrornas in cephalochordates reveals a correlation between microrna repertoire homology and morphological similarity in chordate evolution. Evolution & Development 2009; (11): 41-49
10. Goloshchapov OV, Vavilov VN, Zubarovskaya LS, et al. Fecal calprotectin is a new quantitative biomarker of the acute and chronic "graft versus host" reaction with intestinal involvement after allogeneic transplantation of hematopoietic stem cells. Clinical oncohematology 2011; (1): 61-68
11. Kolho KL, Turner D, Veereman-Wauters G, et al. Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr 2012 Oct; 55 (4): 436-9
12. Sylvester KG, LingXB, Liu GY, et al. A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants. Gut Sep 18, 2013; 25-37
13. Sekacheva Ml. The problem of therapy of inflammatory bowel diseases and ways of their solution. Consilium medicum
2004; 6 (2): 45
14. Zani A, Cananzi М, Fascetti LF, et al. Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism. Gut 2014; (63): 300-309
15. Raboisson M J, Huissoud C, Lapointe A, et al. Assessment of uterine artery and aortic isthmus Doppler recordings as predictors of necrotizing enterocolitis. Am J Obstet Gynecol 2012; 206(3): 232
16. Miner CA, Fullmer S, Eggett DL, Christensen RD. Factors affecting the severity of necrotizing enterocolitis. J Matern Fetal Neonatal Med 2013; 26: 1715-1719
17. Reisinger KW, Van der Zee DC, Brouwers HA, et al. Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid-binding protein in necrotizing enterocolitis. J Pediatr Surg 2012; 47 (9): 1640-1645
18. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease F.Ye. The American Journal of Cardiology 2004; 94 (6): 840-844
19. Khaitov RM, Paschenkov MV, Pinegin BV The role of pattern-recognition receptors in congenital and adaptive immunity. Immunology 2009; 30 (1): 66-76
20. Coorevits L, Baert FJ, Vanpoucke HJ. Fecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2012; (22): 1-7
21. Sydora MJ, Sydora ВС, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. Journal of Crohn'sand Colitis 2012; (6): 207-214
22. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue® rapid test for faecal calprotectin. Ann Clin Biochem 2012; 49(1): 55-8
23. Hessels J, Douw G, Yildirim DD, et al. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin. Clin Chem Lab Med 2012; 50 (6): 79-82
24. Yablokova EA, Orelov AV, Ratnikova MA, et al. Inflammatory bowel diseases in children. Pediatrics 2006; (5): 99-102
25. Szczepaiiski М, Dadalski М, Szymahska Е, et al. Fecal calprotectin is a good biomarker of mucosal healing in monitoring of children with IBD. Postepy Nauk Medycznych 2014; 27 (3): 150-153.
Attachment | Size |
---|---|
2017_02_256-259.pdf | 262.79 KB |